EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A protective hybrid protein vaccine informed by mapping major histocompatibility class II epitopes in Cryptococcus neoformans chitin deacetylases that stimulate CD4 + T-cell responses

Charles A Specht iD, Lorena V N Oliveira iD, Diana Carlson iD, Maureen M Hester iD, Satya Sahu iD, Gabriel Kristian Pedersen iD, Stuart M Levitz iD

mBio · 11.11.2026 · 17 (11)

DOI: 10.1128/mbio.02176-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 11.11.2026. Verfasst von Charles A Specht und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA. Hauptthemen laut MEDLINE: Cryptococcus neoformans, CD4-Positive T-Lymphocytes, Fungal Vaccines, Cryptococcosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institute of Allergy and Infectious Diseases, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infections due to Cryptococcus species are estimated to cause over 100,000 deaths a year. No cryptococcal vaccines are approved for human use. We have shown that vaccine formulations consisting of C. neoformans chitin deacetylase 2 (Cda2) and Cda1 adjuvanted with Cationic Adjuvant Formulation 01 (CAF01) protect mice against experimental cryptococcosis by a mechanism dependent upon CD4 + T cells. Here, using overlapping peptide libraries, we mapped epitopes in Cda2 and Cda1 that stimulated interferon-gamma (IFNγ) release from splenocytes of C57BL/6 and DR4 mice immunized with these proteins. DR4 mice lack mouse major histocompatibility class II (MHC-II) proteins and express chimeric MHC-II proteins with the specificity of the human HLA-DR allele, HLA-DRB1*04:01. Experimental results were then compared with MHC-II binding predictions using the Immune Epitope Database NetMHCIIpan 4.1 BA MHC-II epitope prediction tool. Unique epitopes in Cda2 and Cda1 were discovered for each mouse strain, some of which were not predicted to bind well to MHC-II. CD4 + T cells were responsible for cytokine release as IFNγ production was lost if CD4 + T cells were depleted from the splenocyte population. Finally, we tested a hybrid recombinant protein that consisted of portions of Cda2 and Cda1 containing the MHC-II/CD4 + T-cell epitopes that induce CD4 + T cells in DR4 mice. When administered as a CAF01-adjuvanted vaccine, the hybrid protein protected DR4 mice from an otherwise lethal C. neoformans pulmonary challenge. These results provide a proof of principle regarding the utility of MHC-II/CD4 + T-cell epitope mapping in cryptococcal vaccine development. IMPORTANCE The development of vaccines to prevent cryptococcosis, a fungal disease which causes over 100,000 deaths annually, is a public health priority. We have demonstrated that adjuvanted vaccines containing two Cryptococcus neoformans protein antigens, chitin deacetylase (Cda)2 and Cda1, protect mice against experimental cryptococcosis by a mechanism dependent upon CD4 + T cells. In this study, we determined which 15-amino-acid peptides of Cda2 and Cda1 stimulate CD4 + T cells in C57BL/6 and DR4 mice; the latter mouse strain has human major histocompatibility class II (MHC-II) specificity. We then synthesized a small hybrid protein containing those portions of Cda2 and Cda1 that strongly stimulated CD4 + T-cell responses in DR4 mice. As an adjuvanted vaccine, the hybrid Cda2/1 protein protected DR4 mice from a C. neoformans pulmonary challenge. Thus, CD4 + T-cell/MHC-II epitope mapping experimentally validated the design of a protective multi-epitope protein for use in cryptococcal vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cryptococcus neoformansCD4-Positive T-LymphocytesFungal VaccinesCryptococcosisHistocompatibility Antigens Class IIAmidohydrolasesEpitopes, T-LymphocyteAnimalsMiceMice, Inbred C57BLEpitope MappingProtein Subunit VaccinesFemaleInterferon-gamma

Stichwörter der Autor:innen

Cryptococcus neoformansepitope mappingfungal vaccinesimmunoinformaticspeptide library

Substanzen

Fungal VaccinesHistocompatibility Antigens Class IIProtein Subunit Vaccineschitin deacetylaseAmidohydrolasesEpitopes, T-LymphocyteInterferon-gamma

Autor:innen und Institutionen

  • Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
  • Center for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.

ORCID-Profile: Charles A Specht, Lorena V N Oliveira, Diana Carlson, Maureen M Hester, Satya Sahu, Gabriel Kristian Pedersen, Stuart M Levitz

Förderung

  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS

Zitieren

APA

Specht, C. A., Oliveira, L. V. N., Carlson, D., Hester, M. M., Sahu, S., Pedersen, G. K., & Levitz, S. M. (2026). A protective hybrid protein vaccine informed by mapping major histocompatibility class II epitopes in Cryptococcus neoformans chitin deacetylases that stimulate CD4 + T-cell responses. mBio, 17(11). https://doi.org/10.1128/mbio.02176-26

Vancouver

Specht CA, Oliveira LVN, Carlson D, Hester MM, Sahu S, Pedersen GK, et al. A protective hybrid protein vaccine informed by mapping major histocompatibility class II epitopes in Cryptococcus neoformans chitin deacetylases that stimulate CD4 + T-cell responses. mBio. 2026;17(11). doi:10.1128/mbio.02176-26

BibTeX
@article{Specht2026,
  author = {Specht, Charles A and Oliveira, Lorena V N and Carlson, Diana and Hester, Maureen M and Sahu, Satya and Pedersen, Gabriel Kristian and Levitz, Stuart M},
  title = {A protective hybrid protein vaccine informed by mapping major histocompatibility class II epitopes in Cryptococcus neoformans chitin deacetylases that stimulate CD4 + T-cell responses},
  journal = {mBio},
  year = {2026},
  volume = {17},
  number = {11},
  doi = {10.1128/mbio.02176-26}
}
Kostenlos starten →